De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways

Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells

(2022) Zhe Sun et al.   CANCER RESEARCH

PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer

(2022) Laura Boyero et al.   CELLULAR ONCOLOGY

Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts

(2022) Rebecca Caeser et al.   Nature Communications

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy

(2022) Emilio Francesco Giunta et al.   Frontiers in Medicine

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival

(2022) Chan-Yuan Zhang et al.   LUNG CANCER

Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53

(2021) Peng Jiang et al.   MOLECULAR CELL

PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer

(2021) Xuefeng Li et al.   Journal of Genetics and Genomics

Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation

(2021) Alvaro Quintanal-Villalonga et al.   Cancer Discovery

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

(2021) Joseph M. Chan et al.   CANCER CELL

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

(2021) Kiran Kundu et al.   Translational Lung Cancer Research

MYC, MYCL, and MYCN as therapeutic targets in lung cancer

(2020) Daniel Massó-Vallés et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT signaling pathway

(2020) Zhan Ma et al.   Aging-US

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

(2020) José Trigo et al.   LANCET ONCOLOGY

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

(2020) Álvaro Quintanal-Villalonga et al.   Nature Reviews Clinical Oncology

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)

(2020) Andreas Saltos et al.   Frontiers in Oncology

Lurbinectedin: First Approval

(2020) Anthony Markham   DRUGS

SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures

(2020) Camille Tlemsani et al.   Cell Reports

Plakophilin 1 is methylated and has a tumor suppressive activity in human lung cancer

(2019) Daniela Haase et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

A novel mutation panel for predicting etoposide resistance in small-cell lung cancer

(2019) Zhengang Qiu et al.   Drug Design Development and Therapy

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics

(2018) Léonie Ferrer et al.   Journal of Thoracic Oncology

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

(2018) Rajeswara Rao Arasada et al.   Nature Communications

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

(2018) Anna F Farago et al.   Future Oncology

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

(2018) Nicolas Marcoux et al.   JOURNAL OF CLINICAL ONCOLOGY

Notch-1 signaling activates NF-κB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway

(2016) Li Li et al.   MEDICAL ONCOLOGY

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer

(2013) Jun Ishii et al.   PATHOLOGY INTERNATIONAL

NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM

(2013) J. K. Osborne et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

(2012) A. Vidal et al.   CLINICAL CANCER RESEARCH

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

(2010) JFM Leal et al.   BRITISH JOURNAL OF PHARMACOLOGY

Epithelial-mesenchymal transition in cancer development and its clinical significance

(2009) Masaaki Iwatsuki et al.   CANCER SCIENCE